A U.S. court cleared the path for a trustee suit alleging Bristol Myers Squibb delayed FDA approval of Breyanzi, a gene therapy for non-Hodgkin lymphoma, to avoid milestone payments tied to its 2019 acquisition of Celgene. The claim centers on timing-related obligations included in the deal structure. BMS now faces litigation risk tied to approval cadence, which could become a broader touchpoint for how deal milestones are managed around regulatory review timelines. —